Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +15.32% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +4.14% |
Morningstar's Benchmark | (Russell 2000 Biotech Growth) 50.000% + ( Nasdaq Biotechnology Index) 50.000% | -- |
- Result of AGM
- Transaction in Own Shares
- Additional Investment in Lycia Therapeutics
- Monthly Valuation Update and Factsheet
- Total Voting Rights
- Annual Financial Report
- Notice of AGM
- Monthly Valuation Update and First Quarter Letter
- Portfolio Company Update: Artios Pharma
- New Investment: Obsidian Therapeutics
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 384.69m |
---|---|
Market cap | 547.82m USD |
Total assets | 676.61m USD |
Total expense ratio | 1.97% |
High | 1.42 |
Low | 1.40 |
Previous close | 1.44 |
Average volume | 717.77k |
---|---|
YTD Change | +1.25% |
Beta | 0.6347 |
Diluted NAV (est) | 1.76 |
Diluted NAV (last pub) | 1.76 |
Premium/Discount | -18.75% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of May 24 2024 13:59 BST.
More ▼